Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 7/2008

01-07-2008 | Original Research Article

Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole in Healthy Subjects and in Patients with Schizophrenia

Authors: Dr David W. Boulton, Georgia Kollia, Suresh Mallikaarjun, Bernard Komoroski, Anjali Sharma, Lawrence J. Kovalick, Richard A. Reeves

Published in: Clinical Pharmacokinetics | Issue 7/2008

Login to get access

Abstract

Background and objective: Patients with schizophrenia or bipolar disorder who are experiencing acute behavioural emergencies often require intramuscular injection of antipsychotics for rapid symptom resolution. The efficacy and tolerability of intramuscular aripiprazole injection has been established in agitated inpatients with schizophrenia or bipolar I disorder. The main objective of the two clinical pharmacology studies reported here was to evaluate the pharmacokinetics of aripiprazole after intramuscular dosing in healthy subjects and in patients with schizophrenia, and after intravenous and oral dosing in healthy subjects.
Subjects and methods: Study 1 was an open-label, randomized, three-treatment crossover study in healthy subjects (n= 18) to assess the bioavailability and pharmacokinetics of intramuscular aripiprazole 5 mg and oral aripiprazole 5 mg relative to intravenous aripiprazole 2 mg. Study 2 was an open-label, nonrandomized, escalating-dose study in patients with schizophrenia (n = 32) to evaluate the pharmacokinetics of intramuscular aripiprazole across a range of doses (from 1 mg to 45 mg).
Main outcome measures: The noncompartmental pharmacokinetic parameters for plasma concentrations of aripiprazole and its active metabolite dehydro-aripiprazole were determined. Safety and tolerability data are also summarized.
Results: In study 1, the geometric mean values for the absolute bioavailability of aripiprazole following oral and intramuscular administration were 0.85 and 0.98, respectively. Intramuscular aripiprazole demonstrated more rapid attainment of plasma aripiprazole concentrations than oral aripiprazole (78% and 5% of peak plasma concentration [Cmax] values at 0.5 hours postdose, respectively). The area under the plasma concentration-time curve (AUC) in the first 2 hours was 90% higher after intramuscular administration than after oral administration. For dehydro-aripiprazole, the AUC over the collection interval values were higher, the times to reach the Cmax values were later and the Cmax values were similar for the intramuscular and oral formulations. In study 2, the proportionality of the Cmax and AUC to doses ranging from 1 mg to 45 mg suggests a linear pharmacokinetic profile for intramuscular aripiprazole.
Conclusion: More rapid absorption was observed following intramuscular aripiprazole injection than following oral dosing. These results support the recently reported efficacy of intramuscular aripiprazole for managing agitation in patients with schizophrenia or bipolar I disorder.
Literature
1.
Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302(1): 381–9PubMedCrossRef
2.
Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441(3): 137–40PubMedCrossRef
3.
Stark AD, Jordan S, Allers KA, et al. Interaction of the novel antipsychotic aripiprazole with 5-HT (1A) and 5-HT (2A) receptors: functional receptorbinding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007; 190(3): 373–82CrossRef
4.
Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6(4): 325–37PubMedCrossRef
5.
Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64(9): 1048–56PubMedCrossRef
6.
Beuzen J-N, Schirr K, Pans M, et al. Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study [abstract/poster]. Schizophr Res 2006; 81 Suppl. 3: 39
7.
Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006; 84(1): 77–89PubMedCrossRef
8.
Keck Jr PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67(4): 626–37PubMedCrossRef
9.
Currier GW, Citrome LL, Zimbroff D, et al. Intramuscular aripiprazole in the control of agitation. J Psychiatry Pract 2007; 13(3): 159–69CrossRef
10.
Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44(2): 179–87PubMedCrossRef
11.
Tran-Johnson TK, Sack DA, Marcus R, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68(1): 111–9PubMedCrossRef
12.
Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006; 188(3): 281–92CrossRef
13.
Zimbroff D, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27(2): 171–6PubMedCrossRef
14.
Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46(5): 359–88PubMedCrossRef
15.
Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry 2003; 64 Suppl. 4: 3–9PubMed
16.
Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series: treatment of behavioral emergencies 2005. J Psychiatr Pract 2005; 11 Suppl. 1: 5–108; quiz 110-2PubMedCrossRef
17.
Wood MD, Scott C, Clarke K, et al. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 2006; 546(1–3): 88–94PubMedCrossRef
18.
Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64(15): 1715–36PubMedCrossRef
19.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: text revision (DSM-IV-TR®). 4th ed. Washington, DC: American Psychiatric Press, Inc., 2000CrossRef
20.
Guy W. ECDEU assessment manual for psychopharmacology. Rev ed. Rockville (MD): US Department of Health, Education and Welfare, 1976
21.
Data on file, Bristol-Myers Squibb Company, 2001
22.
Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel-Dekker, Inc., 1982
23.
Data on file, Bristol-Myers Squibb Company/Otsuka Pharmaceutical Development and Commercialization, Inc., 2000
24.
Data on file, Bristol-Myers Squibb Company, 2005
25.
Schwartz ML, Meyer MB, Covino BG, et al. Antiarrhythmic effectiveness of intramuscular lidocaine: influence of different injection sites. J Clin Pharmacol 1974; 14(2): 77–83PubMed
26.
Caritis SN, Venkataramanan R, Cotroneo M, et al. Pharmacokinetics and pharmacodynamics of ritodrine after intramuscular administration to pregnant women. Am J Obstet Gynecol 1990; 162(5): 1215–9PubMed
27.
Lazebnik N, Kuhnert BR, Carr PC, et al. Intravenous, deltoid, or gluteus administration of meperidine during labor? Am J Obstet Gynecol 1989; 160 (5 Pt 1): 1184–9PubMed
28.
Evans EF, Proctor JD, Fratkin MJ, et al. Blood flow in muscle groups and drug absorption. Clin Pharmacol Ther 1975; 17(1): 44–7PubMed
29.
Tuttle CB. Intramuscular injections and bioavailability. Am J Hosp Pharm 1977; 34(9): 965–8PubMed
Metadata
Title
Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole in Healthy Subjects and in Patients with Schizophrenia
Authors
Dr David W. Boulton
Georgia Kollia
Suresh Mallikaarjun
Bernard Komoroski
Anjali Sharma
Lawrence J. Kovalick
Richard A. Reeves
Publication date
01-07-2008
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 7/2008
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200847070-00004